Table 2.

Hematologic malignancy in NHD13 transgenic mice


ID

Age, mo

Necropsy findings

WBCs, 109/L

Hb, g/dL

MCV, fL

Platelets, 109/L

Blasts, %

Diagnosis
1017   9   Splenomegaly   55.3   4.4   69.8   > 15 000   30.0*  Megakaryocytic leukemia  
1018   13   Hepatosplenomegaly   151.1   8.7   58   980   26.8   Pre-T LBL; erythroid leukemia  
1019   13   Hepatosplenomegaly   1.26   10.9   61.9   825   ND   Undifferentiated leukemia  
1145   5   Hyposplenia   0.62   4.0   46.7   586   9.0   MDS  
1149   4   Hyposplenia   ND   ND   ND   ND   48.4   Pre-T LBL  
1897   13   Hepatosplenomegaly   4.9   6.4   71.9   1094   31.8   Undifferentiated leukemia  
1901   9   Hepatosplenomegaly, lymphadenopathy   13.2   8.9   59.7   1472   96.6   Pre-T LBL  
1903
 
9
 
Splenomegaly
 
2.94
 
10.6
 
52.4
 
1239
 
11.0
 
MDS
 

ID

Age, mo

Necropsy findings

WBCs, 109/L

Hb, g/dL

MCV, fL

Platelets, 109/L

Blasts, %

Diagnosis
1017   9   Splenomegaly   55.3   4.4   69.8   > 15 000   30.0*  Megakaryocytic leukemia  
1018   13   Hepatosplenomegaly   151.1   8.7   58   980   26.8   Pre-T LBL; erythroid leukemia  
1019   13   Hepatosplenomegaly   1.26   10.9   61.9   825   ND   Undifferentiated leukemia  
1145   5   Hyposplenia   0.62   4.0   46.7   586   9.0   MDS  
1149   4   Hyposplenia   ND   ND   ND   ND   48.4   Pre-T LBL  
1897   13   Hepatosplenomegaly   4.9   6.4   71.9   1094   31.8   Undifferentiated leukemia  
1901   9   Hepatosplenomegaly, lymphadenopathy   13.2   8.9   59.7   1472   96.6   Pre-T LBL  
1903
 
9
 
Splenomegaly
 
2.94
 
10.6
 
52.4
 
1239
 
11.0
 
MDS
 

Hb indicates hemoglobin; pre-T LBL, precursor T-cell lymphoblastic lymphoma/leukemia; ND, not done; MDS, myelodysplastic syndrome.

*

Percentage of blasts in bone marrow or spleen (no. 1017)

or Create an Account

Close Modal
Close Modal